开云app官网登录入口网页版-官方正版

#I期临床试验#

226篇内容 | 3047人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2207636, encodeId=83d1220e63696, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a> <a href='/topic/show?id=741311505ed9' target=_blank style='color:#2F92EE;'>#晚期胃/胃食管交界处癌#</a>, objectTitle=2024 ASCO｜徐瑞华教授：晚期胃/胃食管交界处癌症患者的Ⅰ期临床试验, objectType=article, longId=828272, objectId=4ccd8282e241, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240531/1717125780457_5579292.jpg, objectUrl=/article/show_article.do?id=4ccd8282e241, replyNumber=0, likeNumber=54, createdTime=2024-05-31, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4ccd8282e241, moduleTitle=2024 ASCO｜徐瑞华教授：晚期胃/胃食管交界处癌症患者的Ⅰ期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4ccd8282e241)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2088879, encodeId=028d20888e9d8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=FDA暂停了苯丙酮尿症（PKU）基因疗法BMN 307的I/II期临床试验, objectType=article, longId=299177, objectId=355f2991e79c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=355f2991e79c, replyNumber=0, likeNumber=84, createdTime=2022-11-26, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=355f2991e79c, moduleTitle=FDA暂停了苯丙酮尿症（PKU）基因疗法BMN 307的I/II期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=355f2991e79c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088878, encodeId=15c820888e8f5, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=南京传奇生物已暂停CAR-T疗法LB1901的I期临床试验, objectType=article, longId=299008, objectId=40752990089a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40752990089a, replyNumber=0, likeNumber=84, createdTime=2023-01-19, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40752990089a, moduleTitle=南京传奇生物已暂停CAR-T疗法LB1901的I期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=40752990089a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088876, encodeId=6e9820888e6f5, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%, objectType=article, longId=219794, objectId=be3b219e94bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be3b219e94bc, replyNumber=0, likeNumber=96, createdTime=2022-04-20, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be3b219e94bc, moduleTitle=乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=be3b219e94bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088873, encodeId=50be20888e3b2, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=靶向IL-4R单克隆抗体 (AK120) 治疗特应性皮炎和哮喘，中国II期临床试验已经启动, objectType=article, longId=218737, objectId=eb23218e37f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb23218e37f3, replyNumber=0, likeNumber=96, createdTime=2022-03-09, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb23218e37f3, moduleTitle=靶向IL-4R单克隆抗体 (AK120) 治疗特应性皮炎和哮喘，中国II期临床试验已经启动, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=eb23218e37f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088875, encodeId=fdc020888e5ea, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展, objectType=article, longId=219261, objectId=3c982192618a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c982192618a, replyNumber=0, likeNumber=90, createdTime=2022-04-25, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c982192618a, moduleTitle=“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3c982192618a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088880, encodeId=803720888804d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, objectType=article, longId=302280, objectId=14b430228084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14b430228084, replyNumber=0, likeNumber=87, createdTime=2022-10-09, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14b430228084, moduleTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=14b430228084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088868, encodeId=3a9e20888686c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖, objectType=article, longId=216995, objectId=8c02216995b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c02216995b9, replyNumber=0, likeNumber=76, createdTime=2022-04-28, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c02216995b9, moduleTitle=2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8c02216995b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088871, encodeId=d49f20888e156, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药, objectType=article, longId=218128, objectId=301e21812880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=301e21812880, replyNumber=0, likeNumber=80, createdTime=2022-09-07, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=301e21812880, moduleTitle=Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=301e21812880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088874, encodeId=1be920888e437, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, objectType=article, longId=218769, objectId=9c2d218e69ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2d218e69ce, replyNumber=0, likeNumber=103, createdTime=2022-04-05, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2d218e69ce, moduleTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9c2d218e69ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088863, encodeId=dbda2088863dd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验, objectType=article, longId=211358, objectId=b3ef2113580f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3ef2113580f, replyNumber=0, likeNumber=83, createdTime=2022-02-04, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3ef2113580f, moduleTitle=J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b3ef2113580f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088869, encodeId=46fe208886914, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=布美他尼用于自闭症III期临床试验失败, objectType=article, longId=217084, objectId=f94e21e084df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f94e21e084df, replyNumber=0, likeNumber=95, createdTime=2022-02-08, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f94e21e084df, moduleTitle=布美他尼用于自闭症III期临床试验失败, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f94e21e084df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088859, encodeId=2ea0208885982, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果, objectType=article, longId=209081, objectId=08c1209081f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08c1209081f4, replyNumber=0, likeNumber=80, createdTime=2021-09-15, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08c1209081f4, moduleTitle=ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=08c1209081f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088872, encodeId=89ed20888e2bf, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点, objectType=article, longId=218304, objectId=0e0c218304c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e0c218304c9, replyNumber=0, likeNumber=101, createdTime=2022-03-25, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e0c218304c9, moduleTitle=糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0e0c218304c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088865, encodeId=3875208886501, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Lancet Infect Dis：陈薇团队研发的雾化吸入用新冠疫苗I期临床试验结果发布, objectType=article, longId=215013, objectId=499f215013f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=499f215013f2, replyNumber=0, likeNumber=0, createdTime=2021-12-17, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=499f215013f2, moduleTitle=Lancet Infect Dis：陈薇团队研发的雾化吸入用新冠疫苗I期临床试验结果发布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=499f215013f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088855, encodeId=045f20888550b, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果, objectType=article, longId=207999, objectId=50a420e99915, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50a420e99915, replyNumber=0, likeNumber=80, createdTime=2022-02-11, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50a420e99915, moduleTitle=抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=50a420e99915)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088877, encodeId=4b2920888e711, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=知临集团宣布完成针对金黄色葡萄球菌和神经母细胞瘤感染的小分子药物ALS-4和SACT-1的I期临床试验, objectType=article, longId=293895, objectId=2b072938950e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b072938950e, replyNumber=0, likeNumber=73, createdTime=2022-05-26, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b072938950e, moduleTitle=知临集团宣布完成针对金黄色葡萄球菌和神经母细胞瘤感染的小分子药物ALS-4和SACT-1的I期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2b072938950e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088851, encodeId=d793208885124, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验, objectType=article, longId=206565, objectId=0ffe20656522, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ffe20656522, replyNumber=0, likeNumber=85, createdTime=2021-06-04, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ffe20656522, moduleTitle=强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0ffe20656522)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088858, encodeId=dd3a208885837, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点, objectType=article, longId=208907, objectId=e5a320890ef2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5a320890ef2, replyNumber=0, likeNumber=64, createdTime=2021-10-06, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5a320890ef2, moduleTitle=CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e5a320890ef2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088864, encodeId=ddb32088864ae, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Nat Med：严重肥胖和代谢综合征患者的粪便微生物移植II期临床试验 , objectType=article, longId=213880, objectId=451f213880fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=451f213880fd, replyNumber=0, likeNumber=79, createdTime=2021-07-11, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=451f213880fd, moduleTitle=Nat Med：严重肥胖和代谢综合征患者的粪便微生物移植II期临床试验 , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=451f213880fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

I期临床试验

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#I期临床试验# #晚期胃/胃食管交界处癌#

2024 ASCO｜徐瑞华教授：晚期胃/胃食管交界处癌症患者的Ⅰ期临床试验

2024-05-31发表于上海

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

FDA暂停了苯丙酮尿症（PKU）基因疗法BMN 307的I/II期临床试验

2022-11-26

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

南京传奇生物已暂停CAR-T疗法LB1901的I期临床试验

2023-01-19

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%

2022-04-20

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

靶向IL-4R单克隆抗体 (AK120) 治疗特应性皮炎和哮喘，中国II期临床试验已经启动

2022-03-09

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展

2022-04-25

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究

2022-10-09

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖

2022-04-28

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药

2022-09-07

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果

2022-04-05

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验

2022-02-04

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

布美他尼用于自闭症III期临床试验失败

2022-02-08

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果

2021-09-15

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点

2022-03-25

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Lancet Infect Dis：陈薇团队研发的雾化吸入用新冠疫苗I期临床试验结果发布

2021-12-17

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果

2022-02-11

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

知临集团宣布完成针对金黄色葡萄球菌和神经母细胞瘤感染的小分子药物ALS-4和SACT-1的I期临床试验

2022-05-26

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验

2021-06-04

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

CureApp与自治医科大学合作开发高血压治疗app：日本III期临床试验达到主要终点

2021-10-06

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Nat Med：严重肥胖和代谢综合征患者的粪便微生物移植II期临床试验

2021-07-11

科室
- - 订阅+
  - 更多科室
工具
服务